FTC Fights Nixing Of AndroGel Reverse Payment Suit

Law360, New York (June 10, 2010, 7:06 PM EDT) -- The Federal Trade Commission is challenging the dismissal of its claims accusing Solvay Pharmaceuticals Inc. of paying generic-drug makers not to compete with its testosterone supplement AndroGel, continuing the fight over so-called reverse payment settlements in the pharmaceutical industry.

In a filing Thursday in the U.S. District Court for the Northern District of Georgia, the FTC said it would appeal the court's April judgment throwing out its allegations with prejudice to the U.S. Court of Appeals for the Eleventh Circuit.

A spokesperson for the agency declined...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.